Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

nue over the remaining period of the Company's original research collaboration with Sigma-Aldrich.

Research and development expenses were $8.7 million for the fourth quarter of 2009, compared to $6.7 million for the same period in 2008.  The increase in research and development expenses was primarily due to expenses related to the initiation of new clinical trials, including a Phase 2b clinical study of SB-509 in moderately severe diabetic neuropathy (DN) and Sangamo's ZFP Therapeutic for the treatment of recurrent glioblastoma, as well as the prosecution of clinical trials for Sangamo's ZFP Therapeutic for HIV/AIDS and increased personnel costs, including non-cash employee stock-based compensation.  

General and administrative expenses were $4.0 million for the fourth quarter of 2009, compared to $2.3 million for the same period in 2008. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation, and professional fees.

Total operating expenses for the fourth quarter of 2009 were $12.7 million, compared to $9.0 million for the same period in 2008.

Net interest income and other income / expense were recorded as income of $22,000 for the fourth quarter of 2009, compared to an expense of $375,000 for the same period in 2008.  The increase was due to a foreign currency translation loss during the prior year quarter.

Full Year Results

For the year ended December 31, 2009, the consolidated net loss was $18.6 million, or $0.44 per share, compared to a net los
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... CHESTER, Pa., April 1, 2008 VWR International,LLC, ... that it,has acquired Jencons (Scientific) Limited, a UK ... the UK,s largest suppliers of laboratory equipment,and consumables ... company also has,operations in Ireland, Kenya and North ...
... and MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris ... a global biopharmaceutical company,focused on endocrine therapy ... a leading Canadian specialty pharmaceutical company, announced ... the transactions under their,previously announced purchase and ...
... 1, 2008 Piedmont Heart Institute (PHI),expands its ... practice, Cardiology of Georgia, P.C. (COG), through a ... With eight,locations including Buckhead, Canton, Fayetteville and North ... the Piedmont Heart Institute and an,important addition to ...
Cached Biology Technology:VWR International, LLC Acquires Jencons (Scientific) Ltd, UK 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... seen the story in the news before. Whether it,s the death ... in August, or of an elderly woman gardening in the middle ... condition for which there is no treatment beyond submersion in ice ... to a normal temperature. But, in a new ...
... of what living cells do is carried out by "molecular ... carry out some biological function. How the minute steps of ... a favorite target for creationists. In a study published ... a team of scientists from the University of Chicago and ...
... warmest since global climate has been measured, and while ... plant communities that reflect this warming trend, no study ... until now. With the publication of "Continent-wide ... Advance Online Publication (AOP) in Nature Climate Change ...
Cached Biology News:'Couch potato pill' might stop heat stroke too 2'Couch potato pill' might stop heat stroke too 3Evolution of complexity recreated using 'molecular time travel' 2Evolution of complexity recreated using 'molecular time travel' 3Evolution of complexity recreated using 'molecular time travel' 4European mountain vegetation shows effects of warmer climate 2